TR10: Dual-Action Antibodies

At Genentech, one of this year’s TR10 innovators, Germaine Fuh is developing a new variety of drug that can target more than one type of molecule, potentially reducing costs and simplifying treatment. We asked Fuh how it worked and what it might mean for patients.

Uh oh–you've read all five of your free articles for this month.

Insider Online Only

$19.95/yr US PRICE

You've read of free articles this month.